Wenbin Jiang Cytek Biosciences, Inc. (CTKB) insider trading activity

Wenbin Jiang is PRESIDENT AND CEO of Cytek Biosciences, Inc.. Currently has a direct ownership of 5.22 Million shares of CTKB, which is worth approximately $20.9 Million. The most recent transaction as insider was on Jun 07, 2023, when has been sold 20,000 shares (Common Stock) at a price of $8.23 per share, resulting in proceeds of $164,600. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.22M

0.72% 3M change

1.49% 12M change

Total Value Held $20.9 Million

Wenbin Jiang Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 07 2023	SELL Open market or private sale	$164,600 $8.23 p/Share	20,000 Reduced 0.26%	7,653,467 Common Stock
May 18 2023	SELL Payment of exercise price or tax liability	$37,356 $6.69 p/Share	5,584 Reduced 0.07%	7,673,467 Common Stock
May 18 2023	BUY Exercise of conversion of derivative security	-	14,612 Added 0.19%	7,676,418 Common Stock
May 08 2023	SELL Open market or private sale	$231,000 $11.55 p/Share	20,000 Reduced 0.26%	7,664,439 Common Stock
Apr 10 2023	SELL Open market or private sale	$177,600 $8.88 p/Share	20,000 Reduced 0.26%	7,684,439 Common Stock
Mar 07 2023	SELL Open market or private sale	$202,600 $10.13 p/Share	20,000 Reduced 0.26%	7,704,439 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$28,884 $10.97 p/Share	2,633 Reduced 0.03%	7,724,439 Common Stock
Feb 21 2023	BUY Exercise of conversion of derivative security	-	6,758 Added 0.09%	7,727,072 Common Stock
Feb 07 2023	SELL Open market or private sale	$263,800 $13.19 p/Share	20,000 Reduced 0.26%	7,720,314 Common Stock
Jan 09 2023	SELL Open market or private sale	$213,200 $10.66 p/Share	20,000 Reduced 0.26%	7,740,314 Common Stock
Dec 07 2022	SELL Open market or private sale	$237,200 $11.86 p/Share	20,000 Reduced 0.26%	7,760,314 Common Stock
Nov 29 2022	SELL Bona fide gift	-	10,000 Reduced 0.13%	7,780,314 Common Stock
Nov 18 2022	SELL Payment of exercise price or tax liability	$33,394 $14.75 p/Share	2,264 Reduced 0.03%	7,790,314 Common Stock
Nov 18 2022	BUY Exercise of conversion of derivative security	-	6,758 Added 0.09%	7,792,578 Common Stock
Nov 07 2022	SELL Open market or private sale	$295,200 $14.76 p/Share	20,000 Reduced 0.26%	7,785,820 Common Stock
Oct 07 2022	SELL Open market or private sale	$295,800 $14.79 p/Share	20,000 Reduced 0.26%	7,805,820 Common Stock
Sep 07 2022	SELL Open market or private sale	$257,800 $12.89 p/Share	20,000 Reduced 0.25%	7,825,820 Common Stock
Aug 18 2022	SELL Payment of exercise price or tax liability	$34,855 $14.06 p/Share	2,479 Reduced 0.03%	7,845,820 Common Stock
Aug 18 2022	BUY Exercise of conversion of derivative security	-	6,758 Added 0.09%	7,848,299 Common Stock
Aug 08 2022	SELL Open market or private sale	$301,800 $15.09 p/Share	20,000 Reduced 0.25%	7,841,541 Common Stock
Jul 07 2022	SELL Open market or private sale	$223,800 $11.19 p/Share	20,000 Reduced 0.25%	7,861,541 Common Stock
Jun 07 2022	SELL Open market or private sale	$215,000 $10.75 p/Share	20,000 Reduced 0.25%	7,881,541 Common Stock
May 18 2022	SELL Payment of exercise price or tax liability	$33,871 $9.65 p/Share	3,510 Reduced 0.04%	7,901,541 Common Stock
May 18 2022	BUY Exercise of conversion of derivative security	-	9,011 Added 0.11%	7,905,051 Common Stock
May 09 2022	SELL Open market or private sale	$160,200 $8.01 p/Share	20,000 Reduced 0.25%	7,896,040 Common Stock

Wenbin Jiang

PRESIDENT AND CEO

Fremont, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTKB shares.

Notify only if

Value

Insider Trading

Get notified when an Cytek Biosciences, Inc. insider buys or sells CTKB shares.

Notify only if

Operation

Value

Type

News

Receive news related to Cytek Biosciences, Inc.

Track Activities on CTKB

Account